Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 17;386(11):1088-1091.
doi: 10.1056/NEJMc2119912. Epub 2022 Jan 26.

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

Rolando Pajon  1 , Nicole A Doria-Rose  2 , Xiaoying Shen  3 , Stephen D Schmidt  4 , Sijy O'Dell  4 , Charlene McDanal  3 , Wenhong Feng  3 , Jin Tong  3 , Amanda Eaton  3 , Maha Maglinao  1 , Haili Tang  3 , Kelly E Manning  5 , Venkata-Viswanadh Edara  5 , Lilin Lai  5 , Madison Ellis  5 , Kathryn M Moore  5 , Katharine Floyd  5 , Stephanie L Foster  5 , Christine M Posavad  6 , Robert L Atmar  7 , Kirsten E Lyke  8 , Tongqing Zhou  4 , Lingshu Wang  4 , Yi Zhang  4 , Martin R Gaudinski  4 , Walker P Black  4 , Ingelise Gordon  4 , Mercy Guech  4 , Julie E Ledgerwood  4 , John N Misasi  4 , Alicia Widge  4 , Nancy J Sullivan  4 , Paul C Roberts  9 , John H Beigel  9 , Bette Korber  10 , Lindsey R Baden  11 , Hana El Sahly  7 , Spyros Chalkias  1 , Honghong Zhou  1 , Jing Feng  1 , Bethany Girard  1 , Rituparna Das  1 , Anne Aunins  1 , Darin K Edwards  1 , Mehul S Suthar  5 , John R Mascola  4 , David C Montefiori  3
Affiliations

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

Rolando Pajon et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Neutralization of D614G and Omicron SARS-CoV-2 Pseudoviruses in Serum Samples Obtained from Recipients of the mRNA-1273 Primary Vaccine Regimen and Booster.
Panel A shows pseudovirus neutralization assay antibody titers against the wild-type D614G and omicron pseudoviruses measured before the administration of the first dose of the primary two-dose mRNA-1273 vaccine on day 1, 1 month after the second dose (day 57), 7 months after the second dose and before the booster dose, and 1 month and 6 months after the 50-μg mRNA-1273 booster dose. The differences in titers relative to D614G are shown. Panel B shows pseudovirus neutralizing assay titers against D614G and omicron pseudovirus in serum samples obtained from vaccine recipients who initially received the two-dose series of mRNA-1273 vaccine (100 μg in each dose) and who subsequently were randomly selected to receive one booster dose of mRNA-1273 vaccine (either 50 or 100 μg), bivalent mRNA-1273.211 vaccine (either 50 or 100 μg), or bivalent mRNA-1273.213 vaccine (100 μg). Serum samples were obtained from the participants 1 month after they received the booster. The time between vaccination with the second dose of primary vaccine and booster vaccination ranged from 7 to 13 months (Table S1). Twenty participants were selected for each dose of the vaccine and the booster and for each type of booster (mRNA-1273, mRNA-1273.211, or mRNA-1273.213 vaccine). The 50% inhibitory dilution (ID50) neutralizing antibody titers were assayed against pseudoviruses containing the spike protein of the D614G and omicron variants (see the Supplementary Methods section in the Supplementary Appendix). The 𝙸 bars represent 95% confidence intervals, and the circles individual participants. The lower limit of detection (dashed line) of the assay was 10. Values below the lower limit of detection were assigned a value of 5. NA denotes not available for testing.
See this image and copyright information in PMC

Update of

References

    1. Hastie KM, Li H, Bedinger D, et al. Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: a global consortium study. Science 2021;374:472-478. - PMC - PubMed
    1. Chu L, McPhee R, Huang W, et al. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine 2021;39:2791-2799. - PMC - PubMed
    1. El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med 2021;385:1774-1785. - PMC - PubMed
    1. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 2022;375:43-50. - PMC - PubMed
    1. Pegu A, O’Connell SE, Schmidt SD, et al. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science 2021;373:1372-1377. - PMC - PubMed

Publication types